US 7,588,760 B2
	Antagonists specific for denatured collagen and methods of using same
Peter C. Brooks, Los Angeles, Calif. (US); Jingsong Xu, Los Angeles, Calif. (US); and Eric Petitclerc, Los Angeles, Calif. (US)
Assigned to University of Southern California, Los Angeles, Calif. (US)
Filed on Jan. 17, 2008, as Appl. No. 12/16,048.
Application 12/016048 is a division of application No. 11/227527, filed on Sep. 15, 2005, granted, now 7,345,151.
Application 11/227527 is a division of application No. 09/478977, filed on Jan. 06, 2000, granted, now 7,122,635.
Claims priority of provisional application 60/114877, filed on Jan. 06, 1999.
Claims priority of provisional application 60/114878, filed on Jan. 06, 1999.
Claims priority of provisional application 60/152496, filed on Sep. 02, 1999.
Claims priority of provisional application 60/143534, filed on Jul. 13, 1999.
Prior Publication US 2009/0028867 A1, Jan. 29, 2009
Int. Cl. A61K 39/395 (2006.01)

U.S. Cl. 424—130.1  [424/141.1]

9 Claims

1. A method for inhibiting angiogenesis in a tumorous tissue comprising administering to a patient a therapeutically effective amount of an antagonist that specifically binds to a denatured collagen or collagens but binds to the native triple helical form of each of said collagens with substantially reduced affinity, wherein said antagonist inhibits angiogenesis, and wherein the antagonist is an antibody is selected from the group consisting of HUIV26, HUI77, and XL313.